Trial sponsor France
GenSight Biologics
GenSight Biologics
Paris-based biotech behind LUMEVOQ (lenadogene nolparvovec), the most extensively studied LHON gene therapy. REFLECT trial (NCT03293524) included Taiwan among 7 countries, with 98 patients enrolled. Regulatory pathway has faced setbacks but product remains accessible through early access programs in EU.
Research focus
GS010 / LUMEVOQlenadogene nolparvovecAAV2-ND4
Public profiles
- Website: https://www.gensight-biologics.com/
Contact is made via official institutional channels, not private email. To request removal, email the project.
Relevant project findings
GenSight represents the Western side of the LHON gene therapy landscape. Cross-border coordination between GenSight and Neurophth could accelerate harmonized outcome measures and global regulatory pathways.
Project outreach status
Not yet contacted